Hospital Acquired Infection Treatment Market to Grow at a CAGR of 1.7% Through 2032 According to a newly published market research report by 24LifeSciences, global Hospital Acquired Infection Treatment market was valued at USD 18.34 billion in 2024 and is projected to reach USD 20.62 billion by 2032, growing at a compound annual growth rate (CAGR) of 1.7% during the forecast period 2025–2032. Hospital Acquired Infections (HAIs), clinically referred to as nosocomial infections, are infections acquired by patients during the course of receiving treatment for other conditions within healthcare facilities, presenting a significant challenge to patient safety worldwide. These infections encompass a range of serious conditions including urinary tract infections, surgical site infections, bloodstream infections, and ventilator-associated pneumonia, among others. The treatment landscape is multifaceted, involving advanced antimicrobial agents, antiseptics, and specialized medical devices designed to combat these pathogens and improve patient outcomes in clinical settings. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/9478/hospital-acquired-infection-treatment-market